Analysts Set Celcuity Inc. (NASDAQ:CELC) Target Price at $29.17

Shares of Celcuity Inc. (NASDAQ:CELC) have been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $29.17.

CELC has been the topic of a number of analyst reports. Stifel Nicolaus lifted their target price on shares of Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, October 7th. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Celcuity in a research note on Friday, November 15th. Lifesci Capital assumed coverage on shares of Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Celcuity in a research note on Friday, November 15th.

Celcuity Stock Down 1.5 %

CELC opened at $12.85 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. Celcuity has a fifty-two week low of $11.51 and a fifty-two week high of $22.19. The firm’s fifty day moving average is $14.83 and its 200 day moving average is $15.81. The stock has a market cap of $477.12 million, a price-to-earnings ratio of -5.00 and a beta of 0.76.

Institutional Trading of Celcuity

Several hedge funds have recently made changes to their positions in the business. Quest Partners LLC raised its position in shares of Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after buying an additional 1,379 shares in the last quarter. Commonwealth Equity Services LLC raised its position in shares of Celcuity by 9.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock valued at $272,000 after buying an additional 1,500 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Celcuity by 7.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after buying an additional 1,600 shares in the last quarter. Acuta Capital Partners LLC raised its position in shares of Celcuity by 3.6% during the 3rd quarter. Acuta Capital Partners LLC now owns 46,600 shares of the company’s stock valued at $695,000 after buying an additional 1,600 shares in the last quarter. Finally, nVerses Capital LLC purchased a new stake in shares of Celcuity during the 3rd quarter valued at about $33,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.